- Home
- AMRN vs CHRS Comparison
AMRN vs CHRS Comparison
Compare AMRN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- CHRS
- Stock Information
- Founded
- AMRN 1989
- CHRS 2010
- Country
- AMRN Ireland
- CHRS United States
- Employees
- AMRN N/A
- CHRS 235
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- CHRS Health Care
- Exchange
- AMRN Nasdaq
- CHRS Nasdaq
- Market Cap
- AMRN 189.2M
- CHRS 134.4M
- IPO Year
- AMRN 1993
- CHRS 2014
- Fundamental
- Price
- AMRN $0.59
- CHRS $1.22
- Analyst Decision
- AMRN Buy
- CHRS Strong Buy
- Analyst Count
- AMRN 1
- CHRS 4
- Target Price
- AMRN N/A
- CHRS $5.38
- AVG Volume (30 Days)
- AMRN 1.1M
- CHRS 2.4M
- Earning Date
- AMRN 02-27-2025
- CHRS 03-12-2025
- Dividend Yield
- AMRN N/A
- CHRS N/A
- EPS Growth
- AMRN N/A
- CHRS N/A
- EPS
- AMRN N/A
- CHRS N/A
- Revenue
- AMRN $241,021,000.00
- CHRS $304,340,000.00
- Revenue This Year
- AMRN N/A
- CHRS $2.47
- Revenue Next Year
- AMRN N/A
- CHRS N/A
- P/E Ratio
- AMRN N/A
- CHRS N/A
- Revenue Growth
- AMRN N/A
- CHRS 44.19
- 52 Week Low
- AMRN $0.43
- CHRS $0.66
- 52 Week High
- AMRN $1.36
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- AMRN 50.48
- CHRS 44.03
- Support Level
- AMRN $0.55
- CHRS $1.03
- Resistance Level
- AMRN $0.61
- CHRS $1.23
- Average True Range (ATR)
- AMRN 0.04
- CHRS 0.13
- MACD
- AMRN -0.00
- CHRS -0.02
- Stochastic Oscillator
- AMRN 26.56
- CHRS 38.89
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.